Want to see COGT full AI Analyst Report?

Cogent Biosciences (COGT) Stock Forecast & Price Target

720 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

COGT Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Cogent

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

COGT Stock 12 Month Forecast

Average Price Target

$52.43

▲(40.75% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Cogent Biosciences in the last 3 months. The average price target is $52.43 with a high forecast of $60.00 and a low forecast of $45.00. The average price target represents a 40.75% change from the last price of $37.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","61":"$61","18.25":"$18.25","32.5":"$32.5","46.75":"$46.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.42857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,18.25,32.5,46.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.81,36.74769230769231,38.68538461538462,40.62307692307692,42.56076923076923,44.49846153846154,46.43615384615385,48.37384615384616,50.31153846153846,52.24923076923077,54.18692307692308,56.12461538461538,58.0623076923077,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.81,36.16527472527473,37.52054945054945,38.87582417582418,40.2310989010989,41.58637362637363,42.941648351648354,44.29692307692308,45.652197802197804,47.00747252747253,48.362747252747255,49.71802197802198,51.073296703296705,{"y":52.42857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.81,35.59384615384616,36.37769230769231,37.16153846153846,37.94538461538462,38.72923076923077,39.51307692307692,40.29692307692308,41.080769230769235,41.864615384615384,42.64846153846154,43.43230769230769,44.216153846153844,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.76,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.89,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.81,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$52.43

Lowest Price Target$45.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert Burns

H.C. Wainwright

$55

Buy

47.65%

Upside

Reiterated

06/18/26

H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)

David Nierengarten

Wedbush

$55

Buy

47.65%

Upside

Reiterated

06/15/26

Wedbush Keeps Their Buy Rating on Cogent Biosciences (COGT)

Laura Prendergast

Stifel Nicolaus

$45

Buy

20.81%

Upside

Reiterated

06/15/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

05/31/26

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT) and Medline (NASDAQ: MDLN)

Michael Yee

UBS

$60

Buy

61.07%

Upside

Reiterated

05/31/26

Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), Cogent Biosciences (NASDAQ: COGT) and Anteris Technologies Global Corp. (NASDAQ: AVR)

Sam Slutsky

LifeSci Capital

$55

Buy

47.65%

Upside

Reiterated

05/09/26

Cogent Biosciences (COGT) Receives a Rating Update from a Top Analyst

Allison Bratzel

Piper Sandler

$52

Buy

39.60%

Upside

Reiterated

05/07/26

Cogent Biosciences (COGT) Gets a Buy from Piper Sandler

Ami Fadia

Needham

―

Hold

―

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)

Michael Schmidt

Guggenheim

$45

Buy

20.81%

Upside

Reiterated

05/06/26

Guggenheim Sticks to Their Buy Rating for Cogent Biosciences (COGT)

Faisal Khurshid

Jefferies

$55

Buy

47.65%

Upside

Initiated

03/16/26

Cogent Biosciences assumed with a Buy at JefferiesCogent Biosciences assumed with a Buy at Jefferies

Colleen M. Kusy

Robert W. Baird

$34→$35

Hold

-6.04%

Downside

Reiterated

02/19/26

Cogent Biosciences price target raised to $35 from $34 at BairdCogent Biosciences price target raised to $35 from $34 at Baird

Christopher Raymond

Raymond James

$60

Buy

61.07%

Upside

Reiterated

01/26/26

Raymond James Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

Andrew Berens

Leerink Partners

$18→$50

Buy

34.23%

Upside

Assigned

11/10/25

Cogent Biosciences price target raised to $50 from $18 at LeerinkCogent Biosciences price target raised to $50 from $18 at Leerink

David Lebowitz

Citi

$22

Buy

-40.94%

Downside

Reiterated

09/04/25

Optimistic Buy Rating for Cogent Biosciences Driven by Bezuclastinib's Potential and Expected 68.2% Share Price Return

Louise Chen

Scotiabank

$17

Buy

-54.36%

Downside

Reiterated

08/06/25

Scotiabank Remains a Buy on Cogent Biosciences (COGT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert Burns

H.C. Wainwright

$55

Buy

47.65%

Upside

Reiterated

06/18/26

H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)

David Nierengarten

Wedbush

$55

Buy

47.65%

Upside

Reiterated

06/15/26

Wedbush Keeps Their Buy Rating on Cogent Biosciences (COGT)

Laura Prendergast

Stifel Nicolaus

$45

Buy

20.81%

Upside

Reiterated

06/15/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

05/31/26

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT) and Medline (NASDAQ: MDLN)

Michael Yee

UBS

$60

Buy

61.07%

Upside

Reiterated

05/31/26

Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), Cogent Biosciences (NASDAQ: COGT) and Anteris Technologies Global Corp. (NASDAQ: AVR)

Sam Slutsky

LifeSci Capital

$55

Buy

47.65%

Upside

Reiterated

05/09/26

Cogent Biosciences (COGT) Receives a Rating Update from a Top Analyst

Allison Bratzel

Piper Sandler

$52

Buy

39.60%

Upside

Reiterated

05/07/26

Cogent Biosciences (COGT) Gets a Buy from Piper Sandler

Ami Fadia

Needham

―

Hold

―

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)

Michael Schmidt

Guggenheim

$45

Buy

20.81%

Upside

Reiterated

05/06/26

Guggenheim Sticks to Their Buy Rating for Cogent Biosciences (COGT)

Faisal Khurshid

Jefferies

$55

Buy

47.65%

Upside

Initiated

03/16/26

Cogent Biosciences assumed with a Buy at JefferiesCogent Biosciences assumed with a Buy at Jefferies

Colleen M. Kusy

Robert W. Baird

$34→$35

Hold

-6.04%

Downside

Reiterated

02/19/26

Cogent Biosciences price target raised to $35 from $34 at BairdCogent Biosciences price target raised to $35 from $34 at Baird

Christopher Raymond

Raymond James

$60

Buy

61.07%

Upside

Reiterated

01/26/26

Raymond James Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

Andrew Berens

Leerink Partners

$18→$50

Buy

34.23%

Upside

Assigned

11/10/25

Cogent Biosciences price target raised to $50 from $18 at LeerinkCogent Biosciences price target raised to $50 from $18 at Leerink

David Lebowitz

Citi

$22

Buy

-40.94%

Downside

Reiterated

09/04/25

Optimistic Buy Rating for Cogent Biosciences Driven by Bezuclastinib's Potential and Expected 68.2% Share Price Return

Louise Chen

Scotiabank

$17

Buy

-54.36%

Downside

Reiterated

08/06/25

Scotiabank Remains a Buy on Cogent Biosciences (COGT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cogent Biosciences

3 Months

Andrew BerensLeerink Partners

Success Rate

9/12 ratings generated profit

Average Return

+23.08%

Copying Andrew Berens's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +23.08% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

12/14 ratings generated profit

Average Return

+161.81%

Copying Anupam Rama's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +161.81% per trade.

2 Years

Robert BurnsH.C. Wainwright

Success Rate

21/22 ratings generated profit

Average Return

+235.50%

Copying Robert Burns's trades and holding each position for 2 Years would result in 95.45% of your transactions generating a profit, with an average return of +235.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

COGT Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, COGT has received 16 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. COGT average Analyst price target in the past 3 months is 52.43.

Each month's total comprises the sum of three months' worth of ratings.

COGT Financial Forecast

COGT Earnings Forecast

Next quarter’s earnings estimate for COGT is -$0.56 with a range of -$0.66 to -$0.44. The previous quarter’s EPS was -$0.53. COGT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year COGT has Performed in-line its overall industry.

COGT Sales Forecast

Next quarter’s sales forecast for COGT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. COGT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year COGT has Performed in-line its overall industry.

COGT Stock Forecast FAQ

What is COGT’s average 12-month price target, according to analysts?

Based on analyst ratings, Cogent Biosciences, Inc.’s 12-month average price target is 52.43.

What is COGT’s upside potential, based on the analysts’ average price target?

Cogent Biosciences, Inc. has 40.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is COGT a Buy, Sell or Hold?

Cogent Biosciences, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Cogent Biosciences, Inc.’s price target?

The average price target for Cogent Biosciences, Inc. is 52.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $45.00. The average price target represents 40.75% Increase from the current price of $37.25.

What do analysts say about Cogent Biosciences, Inc.?

Cogent Biosciences, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of COGT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cogent Biosciences (COGT) Stock Forecast & Price Target

COGT Analyst Ratings

COGT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cogent Biosciences

COGT Analyst Recommendation Trends

COGT Financial Forecast

COGT Earnings Forecast

COGT Sales Forecast

COGT Stock Forecast FAQ

Detailed List of Analyst Forecasts